PMID- 36601066
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 9
DP  - 2022
TI  - Favorable effect of renal denervation on elevated renal vascular resistance in 
      patients with resistant hypertension and type 2 diabetes mellitus.
PG  - 1010546
LID - 10.3389/fcvm.2022.1010546 [doi]
LID - 1010546
AB  - OBJECTIVE: To assess the effect of renal denervation (RDN) on renal vascular 
      resistance and renal function in patients with drug-resistant hypertension (HTN) 
      and type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: Fifty-nine patients 
      (mean age 60.3 +/- 7.9 years, 25 men) with resistant HTN [mean 24-h ambulatory 
      blood pressure (BP) 158.0 +/- 16.3/82.5 +/- 12.7 mmHg, systolic/diastolic] and T2DM 
      (mean HbA1c 7.5 +/- 1.5%) were included in the single-arm prospective study and 
      underwent RDN. Renal resistive index (RRI) derived from ultrasound Doppler; 
      estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology 
      Collaboration formula), office and 24-h ambulatory BP were measured at baseline, 
      6, and 12 months after RDN to evaluate the respective changes in renal vascular 
      resistance, renal function, and BP during treatment. RESULTS: Forty-three 
      patients completed 12 months follow-up. The RRI changed depending on the baseline 
      value. Specifically, the RRI decreased significantly in patients with elevated 
      baseline RRI values >/= 0.7 n = 23; -0.024 [95% confidence interval (CI): -0.046, 
      -0.002], p = 0.035 and did not change in those with baseline RRI < 0.7 [n = 36; 
      0.024 (95% CI: -0.002, 0.050), p = 0.069]. No significant change was observed in 
      eGFR whereas BP was significantly reduced at 12 months after RDN by -10.9 (95% 
      CI: -16.7, -5.0)/-5.5 (95% CI: -8.7, -2.4) mmHg, systolic/diastolic. No 
      relationship was found between the changes in RRI and BP. CONCLUSION: Our study 
      shows that RDN can decrease elevated renal vascular resistance (RRI > 0.7) and 
      stabilize kidney function in patients with RHTN and T2DM independently of its 
      BP-lowering effect.
CI  - Copyright (c) 2022 Manukyan, Falkovskaya, Mordovin, Pekarskiy, Zyubanova, 
      Solonskaya, Ryabova, Khunkhinova, Vtorushina and Popov.
FAU - Manukyan, Musheg
AU  - Manukyan M
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Falkovskaya, Alla
AU  - Falkovskaya A
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Mordovin, Victor
AU  - Mordovin V
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Pekarskiy, Stanislav
AU  - Pekarskiy S
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Zyubanova, Irina
AU  - Zyubanova I
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Solonskaya, Ekaterina
AU  - Solonskaya E
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Ryabova, Tamara
AU  - Ryabova T
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Khunkhinova, Simzhit
AU  - Khunkhinova S
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Vtorushina, Anastasia
AU  - Vtorushina A
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
FAU - Popov, Sergey
AU  - Popov S
AD  - Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology 
      Research Institute, Tomsk, Russia.
LA  - eng
PT  - Journal Article
DEP - 20221214
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC9806766
OTO - NOTNLM
OT  - renal denervation
OT  - renal function
OT  - renal hemodynamics
OT  - renal resistive index
OT  - resistant hypertension
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/06 06:00
MHDA- 2023/01/06 06:01
PMCR- 2022/01/01
CRDT- 2023/01/05 02:23
PHST- 2022/08/03 00:00 [received]
PHST- 2022/11/22 00:00 [accepted]
PHST- 2023/01/05 02:23 [entrez]
PHST- 2023/01/06 06:00 [pubmed]
PHST- 2023/01/06 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2022.1010546 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2022 Dec 14;9:1010546. doi: 10.3389/fcvm.2022.1010546. 
      eCollection 2022.